Gemcitabine + Navelbine + Doxorubicin Hydrochloride Liposome Injection + Granulocyte-colony stimulating factor (G-CSF) + Pegfilgrastim + Cyclophosphamide + Vincristine + Leucovorin + Methotrexate + Doxorubicin Hydrochloride + Cytarabine + Etoposide + Carmustine + Denileukin diftitox
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T-Cell Lymphoma
Conditions
Peripheral T-Cell Lymphoma
Trial Timeline
Jul 1, 2008 → Jun 23, 2016
NCT ID
NCT00632827About Gemcitabine + Navelbine + Doxorubicin Hydrochloride Liposome Injection + Granulocyte-colony stimulating factor (G-CSF) + Pegfilgrastim + Cyclophosphamide + Vincristine + Leucovorin + Methotrexate + Doxorubicin Hydrochloride + Cytarabine + Etoposide + Carmustine + Denileukin diftitox
Gemcitabine + Navelbine + Doxorubicin Hydrochloride Liposome Injection + Granulocyte-colony stimulating factor (G-CSF) + Pegfilgrastim + Cyclophosphamide + Vincristine + Leucovorin + Methotrexate + Doxorubicin Hydrochloride + Cytarabine + Etoposide + Carmustine + Denileukin diftitox is a phase 2 stage product being developed by Eisai for Peripheral T-Cell Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00632827. Target conditions include Peripheral T-Cell Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00632827 | Phase 2 | Terminated |
Competing Products
20 competing products in Peripheral T-Cell Lymphoma